Phase 1 Safety and Tolerability Study of Andes-1537 for Injection in Patients With Advanced Unresectable Solid Tumors

NCT02508441 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
22
Enrollment
INDUSTRY
Sponsor class

Stopped Part 1 of the study was completed and the maximum tolerated dose determined. Part 2 of the study was terminated and will be conducted under a new protocol.

Conditions

Interventions

Sponsor

Andes Biotechnologies